Plerixafor is an inhibitor of CXCR-4 (CXC chemokine receptor-4)/SDF (stromal cell-derived factor)-1 binding used in combination with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood hematopoietic stem cells (HSCs). We developed a data-generated, cost-saving decision-making algorithm that uses the CD34 þ count in the peripheral blood on the fourth day of G-CSF administration (PB-CD34 þ ), and the collection target (T-CD34 þ ) to decide between continuing G-CSF only (G approach) or adding plerixafor to the mobilization regimen (G þ P approach) aiming at the lowest cost. The G þ P approach was more costeffective with lower PB-CD34 þ . It was possible to determine, for each T-CD34 þ , the maximum PB-CD34 þ for which the G þ P approach is cost-effective, generating an algorithm for the use of plerixafor. We validated this algorithm in a cohort of 34 patients undergoing HSC mobilization. In all, 11 patients completed collection on the G approach and 23 patients on the G þ P approach, with 91% of the patients completing collection within the predicted number of apheresis sessions. All patients who underwent transplantation engrafted with minimal differences in engraftment time between G and G þ P approaches. This validated algorithm provides a potential cost-saving decision tool for the use of plerixafor in autologous HSC mobilization.
Introduction
High-dose chemotherapy with autologous hematopoietic stem cell (HSC) transplantation extends survival in patients with multiple myeloma (MM) [1] [2] [3] and relapsed or refractory, chemosensitive lymphomas. [4] [5] [6] Owing to faster engraftment and consequently fewer complications, 7, 8 peripheral blood has almost entirely replaced the BM as the preferred source of HSC for autologous transplantation. Therefore, effective mobilization of HSC with the use of hematopoietic growth factors (such as granulocyte colony-stimulating factor (G-CSF) and/or granulocyte macrophage colony-stimulating factor) [9] [10] [11] [12] [13] alone or combined with chemotherapy agents 9, 12, 13 is necessary. Mobilization with growth factors alone allows a shorter interval between the start of mobilization and transplant and is associated with less morbidity, particularly lower rate of catheter-associated infection and lower rate of hospital admission. 9, 12, 13 Nevertheless, this approach often fails to yield the target number of HSCs, particularly in heavily pretreated patients, 10, 11 patients with previous BM infiltration 11, 14 and patients exposed to lenalidomide. 15, 16 Plerixafor (former AMD 3100) is a SDF (stromal cellderived factor)1alpha/CXCR-4 (CXC chemokine receptor-4) binding inhibitor that produces a predictable peak of CD34 þ cells in the peripheral blood B10 h after its administration. 17, 18 When used concomitantly with growth factor, plerixafor improves the yield of CD34 þ collection and has been shown to successfully mobilize CD34 þ cells in patients failing or likely to fail standard mobilization with growth factor or growth factor combined with chemotherapy. 19, 20 In two recent phase 3 studies, the addition of plerixafor on and beyond the fourth day of G-CSF administration reduced the number of apheresis days and increased the yield of CD34 þ cell mobilization in patients with MM 21 and non-Hodgkin's lymphoma (NHL), 22 when compared with G-CSF alone. Mostly, on the basis of these two trials, plerixafor was approved in the United States for mobilization of HSC before autologous transplantation in MM and NHL patients.
The use of plerixafor in all MM and lymphoma patients undergoing HSC mobilization is not necessary and is unlikely to be cost-effective. Mobilization algorithms are required to guide the use of plerixafor aiming not only at better collection yields but also at cost-effectiveness and better utilization of available resources.
We have established a decision-making algorithm that uses the target number of CD34 þ cells to be collected and the CD34 þ cell count in peripheral blood on the fourth day of mobilization with G-CSF to determine whether to use plerixafor. In this study, we present the development of this algorithm and its validation in a cohort of 34 patients.
Materials and methods
On clinical trials leading to its regulatory approval in the United States, plerixafor was used daily, starting on the night of day 4 of mobilization, with apheresis starting on day 5, and continuing until the collection target is met, regardless of PB-CD34 þ . Recognizing the expected correlation between PB-CD34 þ and the average daily apheresis product (AP-CD34 þ ), we hypothesized that beyond a certain PB-CD34 þ , the collection process with continuation of G-CSF only would be satisfactory and the use of plerixafor would not be cost-effective. This PB-CD34 þ value should depend on the target CD34 þ for the entire collection process (T-CD34 þ ). This study aimed to determine the maximum PB-CD34 þ , for a given T-CD34 þ , for which the use of plerixafor is still costeffective; therefore, a decision can be made on the fourth day of mobilization to proceed with apheresis and daily G-CSF or to add plerixafor and start apheresis on day 5.
Relationship between peripheral blood CD34 count and apheresis product We reviewed mobilization and collection data in 50 historical consecutive mobilizations without the use of plerixafor in lymphoma and MM patients from our program to establish a mathematical correlation between peripheral blood CD34 þ cell count on the first day of apheresis (PB-CD34 þ ) and average CD34 þ cell count in the daily apheresis product (AP-CD34 þ ). This mathematical correlation was used in the final model to estimate AP-CD34 þ based on PB-CD34 þ without the use of plerixafor.
The magnitude of AP-CD34 þ -fold increase with the use of plerixafor is variable and altered by apheresis equipment and blood volume processed. 22, 23 It is also likely to change across the range of PB-CD34 þ values with higher fold increments observed with lower PB-CD34 þ values. 23 DiPersio et al. 21 showed that the addition of plerixafor to G-CSF in the mobilization regimen leads to an approximate three-fold increase (from 2.29 to 7.01 Â 10 6 CD34 þ cells per kg) in AP-CD34 þ on the first day of apheresis in a randomized trial addressing the use of plerixafor for mobilization in MM patients. In a cross-over study by Flomenberg et al., 23 the use of plerixafor combined with G-CSF allowed a four-fold increase in AP-CD34 þ when compared with the use of G-CSF alone. On the basis of these two sets of data, we estimated that the addition of daily plerixafor starting on day 4 of mobilization with G-CSF would lead to a near three-fold increase in the estimated AP-CD34 þ that would be obtained with continuation of G-CSF only Estimation of number of apheresis sessions and mobilization charges The projected numbers of days of apheresis with the approaches of continuing G-CSF alone or adding plerixafor to the mobilization regimen, N G and N G þ P , respectively, were estimated by rounding up to the next natural number (as there is no 'fraction' for an apheresis session) the ratio between T-CD34 þ and AP-CD34 þ for the corresponding approach.
In estimating the charges for each approach, only reoccurring charges were included as fixed charges (for example, apheresis line placement) were not expected to differ between the two approaches. Medication doses were based on a 75 kg individual and used the listed average wholesale price for each product.
For this analysis, the estimated daily charges for G-CSF (filgrastim) administration (F) were US$768.90 and for plerixafor (P) were US$7812.00. The average daily charges for apheresis (A) were US$6922.00. Estimated A charges included physician, facility, equipment and cryopreservation fees and were based on the historical charges in our program. Therefore, for a given estimated number of apheresis sessions required with the G-CSF approach (N G ), the recurring charges are estimated to be
Similarly, for a given estimated number of apheresis sessions required with a G-CSF þ Plerixafor approach (N G þ P ), the recurring charges are estimated to be
For a given T-CD34 þ and a given PB-CD34 þ , the algorithm allows the patient to pursue the approach (G or G þ P) with the lowest projected final charge.
Validation of the algorithm
Immediately after the development of the above-described algorithm, we implemented it at our center as a quality improvement measure. The apheresis equipment used for the mobilizations reviewed in the historical series and in the validation cohort was a COBE Spectra (Gambro BCT, Lakewood, CO, USA), software version 6.1 and at least three total blood volumes were processed in each daily apheresis session.
We subsequently obtained approval from the institutional review board to review mobilization and transplant records for all patients undergoing G-CSF mobilization with and without plerixafor, since the implementation of the algorithm.
The main parameter analyzed to evaluate the accuracy of the algorithm was the proportion of patients meeting the prespecified T-CD34 þ within the predicted number of apheresis procedures, with the use of plerixafor being determined by the algorithm. A secondary measurement of accuracy was the comparison between predicted and actual AP-CD34 þ . In addition, we extracted engraftment parameters for the patients who have already undergone HSC transplantation after mobilization using this algorithm.
Statistics
We reported proportions with their respective 95% confidence intervals. Comparisons between proportions were made using Fisher's exact test. The strength of the linear relationship between two variables was calculated as the square of the Pearson product moment correlation coefficient (r). Continuous numerical variables were described using their median and range. Comparisons between continuous variables used the Mann-Whitney U-test. In all inference analyses, two-sided P-values o0.05 were considered to indicate statistical significance.
Results

Algorithm development
The review of 50 consecutive mobilizations in our program allowed the establishment of a mathematical correlation between PB-CD34 þ and AP-CD34 þ . In 10 of these mobilizations, PB-CD34 þ was X100 cells per mm 3 and these cases were excluded from the model. These 10 excluded patients reached the collection target in one apheresis session (9.2-34.7 Â 10 6 CD34 þ per kg). Their inclusion in the model would have led to significant distortion in the mathematical correlation between PB-CD34 þ and AP-CD34 þ at lower PB-CD34 þ levels (particularly relevant for this study). The linear function predicting AP-CD34 based on PB-CD34 þ is based on the remaining 40 collections (Figure 1) .
The projected AP-CD34 þ is best predicted by the equation
The estimated daily yield if the patient proceeds in the G approach is a simple readout of the corresponding AP-CD34 þ in the curve displayed in Figure 2 for the respective PB-CD34 þ level. On the basis of the available literature 21, 23 and as explained in the 'Materials and methods' section, the addition of daily plerixafor on the fourth day of G-CSF mobilization (G þ P approach) is expected to increase AP-CD34 þ by approximately threefold. Therefore, the equation that best predicts AP-CD34 þ with the G þ P approach is AP-CD34 þ ¼ 3 Â (PB-CD34 þ Â 131 857-389 334). With these two equations and as explained in the 'Materials and methods' section, it is possible to estimate the number of days required to complete the collection on the basis of PB-CD34 þ and T-CD34 þ using the G or G þ P approach (Figure 3) . Using the above-described methodology, it is now possible to estimate the total of recurring mobilization charges with each approach for a given PB-CD34 þ and T-CD34 þ . As expected, higher PB-CD34 þ values are linked to lower predicted charges with the G approach, whereas lower PB-CD34 þ predicts a financial advantage with the addition of plerixafor to the mobilization regimen on day 4 and beyond. By estimating the total charge expected with each combination of PB-CD34 þ and T-CD34 þ , it is possible to determine the highest PB-CD34 þ for a prespecified T-CD34 þ that is linked to the reduction in charges with the use of plerixafor (Figure 3) . In essence, such information supports the decision on day 4 of G-CSF mobilization either to proceed with apheresis and daily G-CSF administration or to add plerixafor to the mobilization regimen aiming at the lowest possible charge from mobilization.
Validation
Upon approval of plerixafor by the United States Food and Drug Administration, we promptly developed and implemented this algorithm to guide the use of plerixafor in our transplant program. A total of 34 patients completed mobilization and 33 (97%) reached the prespecified T-CD34 þ . The T-CD34 þ was either 6 Â 10 6 CD34 þ per kg (for MM patients collecting after initial therapy and aiming at up to two transplants, N ¼ 16) or 3 Â 10 6 CD34 þ per kg (for all remaining patients, N ¼ 18). The clinical characteristics of these patients are displayed in Table 1 .
In all, 11 (32%) patients completed collection in the G approach and 23 (68%) patients in the G þ P approach (Figure 3 ) as dictated by their targets and PB-CD34 þ . The median actual number of CD34 þ per kg collected was 129% of the target with the G approach (interquartile range: 105-141%) and 166% with the G þ P approach (interquartile range: 112-231%), P ¼ 0.22. The average daily AP-CD34 was 103% of predicted (interquartile range: 80-113%) for the G approach and 260% (interquartile range: 207-379%) for the G þ P approach. Overall, 97% of patients met their mobilization target and 94% (81.9% for G and 95.7% for G þ P, P ¼ 0.18) completed collection within the predicted number of apheresis sessions. The median number of days of apheresis was 2 for patients in the G approach and 1 for patients in the G þ P approach. The most important inaccuracy of the model was that it underestimated the impact of plerixafor in patients with PB-CD34 þ p10 per mm 3 . In all, 12 of the 13 patients in this range completed collection on the G þ P approach in less days than was predicted by the model (median number of actual days ¼ 2; median number of predicted days ¼ 4). This deficiency, however, is irrelevant for day 4 decision making as these patients are unlikely to successfully meet their T-CD34 þ with G-CSF mobilization alone and in most institutions would not even initiate apheresis.
A total of 26 (76%) of the patients included in the validation cohort have undergone an autologous HSC transplantation. The median cell dose was 3.9 Â 10 6 (interquartile range: 3.2-4.2 Â 10 6 ) CD34 þ per kg for the 9 patients in the G approach and 4.2 Â 10 6 (interquartile range: 3.3-6.2 Â 10 6 ) CD34 þ per kg for the 17 patients in the G þ P approach. All patients met the criteria for engraftment. Patients mobilized with the G approach had slightly faster time to ANC4500 per mm 2 (median 12 vs 13 days, P ¼ 0.04) and to platelet count 420 000 per mm 2 without platelet transfusion (median 12 vs 16 days, P ¼ 0.02).
Discussion
Since plerixafor was made available, there has been intense debate on the appropriate settings for its utilization. 24, 25 One option consists of the use of plerixafor starting on the fourth day of G-CSF mobilization if PB-CD34 þ fails to achieve a certain threshold (for example, 10 CD34 þ cells per mm 3 ). 26 This approach benefits from the knowledge of a correlation between PB-CD34 þ and AP-CD34 þ and indicates the use of plerixafor for patients who are unlikely to reach a certain CD34 þ target.
Our algorithm adopts the concept of adjusting the mobilization plan according to PB-CD34 þ , but improves upon this concept by incorporating an analysis of financial charges. It also provides different 'plerixafor thresholds' to various possible T-CD34 þ , instead of using an arbitrary threshold PB-CD34 þ , still allowing for same day decision.
The easy applicability and accuracy of this algorithm were confirmed by the 34 consecutive patient validation cohort. Many of these patients had risk factors for mobilization failure with G-CSF alone (Table 1) . Other factors that illustrate the high risk for mobilization failure with G-CSF alone in the validation cohort are the low median PB-CD34 þ on day 4 (12 per mm 3 ) and the high proportion (38%) of patients with PB-CD34 þ o10 mm 3 on day 4. The demonstrated predictability of the collection process is another potential advantage of this algorithm as it could allow more accurate scheduling of apheresis sessions and consequently better utilization of the apheresis resources.
One major barrier to present a more detailed cost analysis is the high proportion of patients in the validation cohort who were likely to fail G-CSF alone mobilization. A comparison between the algorithm and G-CSF mobilization would be impossible as the model cannot predict the cost of mobilization with G-CSF alone for patients who have a PB-CD34 þ o10 and who would likely not initiate apheresis and instead would undergo a second round of G-CSF mobilization, combined with or without CY, or undergo BM harvesting if plerixafor was not available.
As plerixafor is approved for use in combination with G-CSF for mobilization in NHL and MM patients regardless of PB-CD34 þ count, we compared the projected cost of mobilization with G and G þ P in the 11 patients in the validation cohort who were able to collect with G alone (and therefore 'saved' the expense of plerixafor). The assignment of these patients to the G approach had a median projected saving of US$2589 per patient. The use of this algorithm also seems to overcome some of the limitations of mobilization with growth factor only (without cytotoxic chemotherapy), such as low CD34 þ yield and high failure rate, particularly in heavily pretreated patients and patients previously exposed to lenalidomide. 10, 11, 13, 15, 16 In fact, all but 1 of the 14 patients previously exposed to lenalidomide completed collection within the predicted number of days.
One pitfall of the algorithm is that it underestimates the impact of plerixafor in increasing AP-CD34 þ in patients with very low PB-CD34 þ . This caused great discrepancy between estimated number and actual number of apheresis days in patients with PB-CD34 þ p10 per mm 3 with the actual number being consistently less than the predicted number. The reason for such discrepancy seems to be that the increase in AP-CD34 þ with the use of plerixafor in patients with very low PB-CD34 þ greatly exceeds threefold, the factor used in the present model, as evidenced in the sequential mobilization study by Flomenberg et al. 23 This discrepancy, however, does not affect the applicability of the algorithm because at very low PB-CD34 þ counts (p10 per mm 3 ) the algorithm indicates the use of plerixafor even for very conservative T-CD34 þ (2 Â 10 6 per kg). There are several factors that can limit the application of the final algorithm across multiple programs. The correlation between peripheral blood CD34 þ count and apheresis yield verified in our center may require confirmation at individual programs. Many factors such as apheresis equipment, apheresis protocol and cell counting technique have a role in that correlation; therefore, each program may have to find its own mathematical equation to accurately predict AP-CD34 þ based on PB-CD34 þ . Even more variability is expected in the charges associated with mobilization and collection with obvious consequences to the final decision-making algorithm. Instead of providing a 'ready-for-use' algorithm, this study delineates the steps necessary for each program to develop its own cost-effectiveness protocol.
Further validation of this approach in a prospective multi-institutional setting would be necessary by comparison with the use of plerixafor in all MM and NHL patients undergoing mobilization and/or with an alternative algorithm (for example, use of plerixafor in patients with PB-CD34 þ less than a prespecified threshold). Such a trial would have to be designed not only with the traditional mobilization end points but also with detailed cost analysis.
